PURPOSE: We determined the role of opioid and metabotropic glutamate 5 receptors in the pudendal inhibition of bladder overactivity. MATERIALS AND METHODS: Cystometrograms were performed in 11 cats under α-chloralose anesthesia by slowly infusing the bladder with saline or 0.25% acetic acid. Pudendal nerve stimulation at intensities of multiple times the threshold to induce observable anal twitching was applied during cystometrogram to inhibit the bladder overactivity induced by acetic acid irritation. Naloxone (0.1, 0.3 and 1 mg/kg intravenously) was administered to block opioid receptors, followed by MTEP (3 and 10 mg/kg intravenously) to block metabotropic glutamate 5 receptors. After each drug dose, pudendal inhibition of bladder overactivity was examined during cystometrogram. RESULTS: Acetic acid irritated the bladder, induced bladder overactivity and significantly decreased mean ± SE bladder capacity to 23.6% ± 2.7% of saline control capacity. Pudendal nerve stimulation at 1 to 1.5 and 4 × threshold suppressed bladder overactivity and significantly increased mean capacity to 57.5% ± 8.1% (p = 0.0005) and 106% ± 15% (p = 0.0002), respectively, of saline control capacity. Naloxone had no effect on pudendal inhibition but MTEP eliminated the inhibition induced by low intensity stimulation and significantly decreased the inhibition induced by high intensity stimulation (p <0.05). Neither naloxone nor MTEP altered baseline bladder overactivity. CONCLUSIONS: Opioid receptors are not involved in pudendal inhibition of bladder overactivity but metabotropic glutamate 5 receptors are partially involved. Understanding neurotransmitter mechanisms could improve the efficacy of neuromodulation therapy for overactive bladder and identify molecular targets for developing new drugs for overactive bladder.
PURPOSE: We determined the role of opioid and metabotropic glutamate 5 receptors in the pudendal inhibition of bladder overactivity. MATERIALS AND METHODS: Cystometrograms were performed in 11 cats under α-chloralose anesthesia by slowly infusing the bladder with saline or 0.25% acetic acid. Pudendal nerve stimulation at intensities of multiple times the threshold to induce observable anal twitching was applied during cystometrogram to inhibit the bladder overactivity induced by acetic acid irritation. Naloxone (0.1, 0.3 and 1 mg/kg intravenously) was administered to block opioid receptors, followed by MTEP (3 and 10 mg/kg intravenously) to block metabotropic glutamate 5 receptors. After each drug dose, pudendal inhibition of bladder overactivity was examined during cystometrogram. RESULTS:Acetic acid irritated the bladder, induced bladder overactivity and significantly decreased mean ± SE bladder capacity to 23.6% ± 2.7% of saline control capacity. Pudendal nerve stimulation at 1 to 1.5 and 4 × threshold suppressed bladder overactivity and significantly increased mean capacity to 57.5% ± 8.1% (p = 0.0005) and 106% ± 15% (p = 0.0002), respectively, of saline control capacity. Naloxone had no effect on pudendal inhibition but MTEP eliminated the inhibition induced by low intensity stimulation and significantly decreased the inhibition induced by high intensity stimulation (p <0.05). Neither naloxone nor MTEP altered baseline bladder overactivity. CONCLUSIONS: Opioid receptors are not involved in pudendal inhibition of bladder overactivity but metabotropic glutamate 5 receptors are partially involved. Understanding neurotransmitter mechanisms could improve the efficacy of neuromodulation therapy for overactive bladder and identify molecular targets for developing new drugs for overactive bladder.
Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein Journal: Neurourol Urodyn Date: 2002 Impact factor: 2.696
Authors: Philip E V van Kerrebroeck; Anco C van Voskuilen; John P F A Heesakkers; August A B Lycklama á Nijholt; Steven Siegel; U Jonas; Clare J Fowler; Magnus Fall; Jerzy B Gajewski; Magdy M Hassouna; Francesco Cappellano; Mostafa M Elhilali; Douglas F Milam; Anurag K Das; H E Dijkema; Ubi van den Hombergh Journal: J Urol Date: 2007-09-17 Impact factor: 7.450
Authors: K Walker; A Reeve; M Bowes; J Winter; G Wotherspoon; A Davis; P Schmid; F Gasparini; R Kuhn; L Urban Journal: Neuropharmacology Date: 2001 Impact factor: 5.250
Authors: W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein Journal: World J Urol Date: 2002-11-15 Impact factor: 4.226
Authors: Bradford D Fischer; Laurence L Miller; Fredrick E Henry; Mitchell J Picker; Linda A Dykstra Journal: Psychopharmacology (Berl) Date: 2008-04-08 Impact factor: 4.530
Authors: Abhijith D Mally; Fan Zhang; Yosuke Matsuta; Bing Shen; Jicheng Wang; James R Roppolo; William C de Groat; Changfeng Tai Journal: J Urol Date: 2012-10-22 Impact factor: 7.450
Authors: Marc J Rogers; Zhiying Xiao; Bing Shen; Jicheng Wang; Zeyad Schwen; James R Roppolo; William C de Groat; Changfeng Tai Journal: Am J Physiol Regul Integr Comp Physiol Date: 2014-11-12 Impact factor: 3.619
Authors: Matthew C Ferroni; Rick C Slater; Bing Shen; Zhiying Xiao; Jicheng Wang; Andy Lee; James R Roppolo; William C de Groat; Changfeng Tai Journal: Am J Physiol Renal Physiol Date: 2015-05-27
Authors: Thomas W Fuller; Xuewen Jiang; Utsav Bansal; Vladimir Lamm; Bing Shen; Jicheng Wang; James R Roppolo; William C de Groat; Changfeng Tai Journal: Am J Physiol Regul Integr Comp Physiol Date: 2016-12-14 Impact factor: 3.619
Authors: Xuewen Jiang; Michelle Yu; Jamie Uy; Thomas W Fuller; Cameron Jones; Bing Shen; Jicheng Wang; James R Roppolo; William C de Groat; Changfeng Tai Journal: Am J Physiol Renal Physiol Date: 2016-12-07
Authors: Jerzy B Gajewski; Anthony J Kanai; Linda Cardozo; Youko Ikeda; Irina V Zabbarova Journal: Neurourol Urodyn Date: 2014-05-16 Impact factor: 2.696
Authors: Zhiying Xiao; Jeremy Reese; Zeyad Schwen; Bing Shen; Jicheng Wang; James R Roppolo; William C de Groat; Changfeng Tai Journal: Am J Physiol Renal Physiol Date: 2014-02-12